Clinical trials
Terminated Thalassemia trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
19 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 1 |
| 2004 | 2 |
| 2007 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 19 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Baylor College of Medicine | 3 |
| Bellicum Pharmaceuticals | 3 |
| Children's Hospital Los Angeles | 1 |
| Columbia University | 1 |
| Emory University | 1 |
| Gamida Cell ltd | 1 |
| Ionis Pharmaceuticals, Inc. | 1 |
| Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | 1 |
| Masonic Cancer Center, University of Minnesota | 1 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Thalassemia | 19 |
| Anemia, Sickle Cell | 13 |
| Hemoglobinopathies | 7 |
| Anemia, Diamond-Blackfan | 6 |
| Anemia, Aplastic | 4 |
| Fanconi Anemia | 4 |
| Granulomatous Disease, Chronic | 4 |
| beta-Thalassemia | 4 |
| Leukemia, Myeloid, Acute | 3 |
| Lymphoma, Non-Hodgkin | 3 |
Trials
Showing 51 to 19 of 19. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.